| Issue |
E3S Web Conf.
Volume 271, 2021
2021 2nd International Academic Conference on Energy Conservation, Environmental Protection and Energy Science (ICEPE 2021)
|
|
|---|---|---|
| Article Number | 03025 | |
| Number of page(s) | 7 | |
| Section | Research on Energy Chemistry and Chemical Simulation Performance | |
| DOI | https://doi.org/10.1051/e3sconf/202127103025 | |
| Published online | 15 June 2021 | |
Current status of immunotherapy in acute myeloid leukemia
Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
* Corresponding author: lwr_01@sjtu.edu.cn
Acute myeloid leukemia (AML) is a rapidly progressive, poor prognosis malignant tumor caused by hematopoietic stem cells/progenitor cells. In recent years, there have been significant advances in basic and preclinical research on AML. Compared with traditional chemotherapy, hematopoietic stem cell transplantation (HSCT) significantly improved prognosis. However, with high recurrence rates and low 5-year survival rates, more and more attention has been focused on immunotherapy strategies for AML. Given the immunological characteristics of AML and the mechanisms of immune escape, ongoing efforts are aimed at improving the strategy of immunotherapy and the design of novel therapies, such as vaccines, monoclonal antibodies, chimeric receptor-engineered T cells (CAR-T), and checkpoint inhibitors, which hopefully can deliver higher specificity and efficacy in AML therapy. In this review, we provide an overview of the immunological characteristics of conventional AML therapies, explore immune avoidance mechanisms, and describe the mechanisms of active and passive immunotherapies and current clinical trials.
© The Authors, published by EDP Sciences, 2021
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.